Hypoglycemia News and Research

RSS

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.

Meals to Live launches new Glucose Quick Sticks to treat low blood sugar

Meals to Live, the first and only grocery store line of frozen meals created specifically for people living with diabetes, adds a new product to its line - Glucose Quick Sticks, an easy-to-carry, quick-dissolving flavored powder packet that provides a healthy boost of glucose for those with challenges.

14 Nov 2011

Sitagliptin as safe and effective as glipizide in patients with type 2 diabetes, CKD

Some blood-sugar-lowering drugs have caused kidney problems in patients with type 2 diabetes, so physicians are especially cautious when prescribing these agents to diabetics who also have chronic kidney disease.

14 Nov 2011

Medtronic initiates enrollment in Enlite Sensor study for diabetes

Medtronic, Inc. today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in adults with diabetes of its Enlite Sensor, the company's latest innovation in continuous glucose monitoring (CGM) technology for people with diabetes.

From Medtronic 10 Nov 2011

More than half of all Americans will have diabetes by 2020

Half of all American adults are destined to develop diabetes or pre-diabetes by 2020 if they don't make dramatic lifestyle changes, according to a dire new prediction from the Centers for Disease Control and Prevention.

5 Nov 2011

Isis commences ISIS-GCGRRx and ISIS-GCCRRx Phase 1 studies for type 2 diabetes

Isis Pharmaceuticals, Inc. announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.

2 Nov 2011

FDA approves Medtronic's LGS IDE for clinical trial to treat Type 1 diabetes

In our continued commitment to develop an artificial pancreas, Medtronic, Inc. today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) to conduct a pivotal in-home clinical trial protocol for the ASPIRE study of the MiniMed Paradigm System featuring Low Glucose Suspend (LGS) automation.

From Medtronic 29 Oct 2011

Innovative trial project of MD-Logic Artificial Pancreas takes place in Israel

At the initiative, and under the leadership of specialists in the Jesse Z and Sara Lea Shaffer Institute for Endocrinology and Diabetes, National Center of Childhood Diabetes, Schneider Children's Medical Center, an innovative trial project of the MD-Logic Artificial Pancreas (MDLAP) has successfully taken place in Israel.

27 Oct 2011

Penn Nursing experts available to discuss stories on American Diabetes Month

Diabetes specialists at the University of Pennsylvania School of Nursing are available to talk with media for stories on American Diabetes Month.

27 Oct 2011

Higher diabetes rates in African American women after GDM

African American women who develop gestational diabetes mellitus during pregnancy face a 52 percent increased risk of developing diabetes in the future compared to white women who develop GDM during pregnancy, according to a Kaiser Permanente study published online in the journal Diabetologia.

21 Oct 2011

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

The US Food and Drugs Administration (FDA) has approved Byetta (exenatide) injection as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without.

20 Oct 2011

Takeda commences TAK-875 Phase 3 clinical trial program for type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiaries, Takeda Global Research & Development Center, Inc., and Takeda Global Research & Development Centre (Europe), Ltd., announced today the initiation of the Company's Phase 3 clinical trial program for TAK-875, an investigational therapy for type 2 diabetes.

18 Oct 2011

Echo Therapeutics to begin Symphony tCGM System clinical study in Type 1 and Type 2 diabetes

Echo Therapeutics, Inc., a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced that it is initiating a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 diabetes.

13 Oct 2011

Endocrine Society releases clinical practice guideline on continuous glucose monitoring

Patients with diabetes face daily challenges in managing their blood glucose levels, and it has been postulated that patients could benefit from a system providing continuous real-time glucose readings. Today, The Endocrine Society released a clinical practice guideline (CPG) providing recommendations on settings where patients are most likely to benefit from continuous glucose monitoring.

12 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

Selected prescription drugs contribute to 10% of lower urinary tract symptoms among men

Use of selected prescription medications, including antidepressants, antihistamines, bronchodilators, anticholinergics, sympathomimetics, and diuretics contribute to 10 percent of lower urinary tract symptoms among men according to a Kaiser Permanente study published in the Archives of Internal Medicine.

11 Oct 2011

Rare and severe hypoglycemia could be genetic

The life-threatening condition depicts the fact that the body does not have enough energy to function. Scientists at the University of Cambridge say mutations in the AKT2 gene are to blame. Writing in the journal Science, they say there are already cancer drugs which target a similar process.

10 Oct 2011

Ford researchers develop series of in-car health and wellness apps, services

Researchers at Ford have developed a series of in-car health and wellness apps and services aimed at monitoring people with chronic illnesses or medical disorders so they can manage their condition while on the go.

From Medtronic 10 Oct 2011

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011

Scientists discover rare genetic alteration responsible for hypoglycaemia

Cambridge scientists have identified the cause of a rare, life-threatening form of hypoglycaemia. Their findings, which have the potential to lead to pharmaceutical treatments for the disorder, were published today, 07 October, in the journal Science.

7 Oct 2011

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Boehringer Ingelheim Canada and Eli Lilly Canada today announced that Health Canada has approved Trajenta (linagliptin), a new oral therapy to improve glycemic control in Canadian adults with type 2 diabetes.

3 Oct 2011